SLC22A5 Deficiency (Primary Carnitine Deficiency)
Lifelong oral L-carnitine supplementation at 50-400 mg/kg/day divided into three doses is the definitive treatment for SLC22A5 deficiency (primary carnitine deficiency), and must be initiated immediately upon diagnosis to prevent life-threatening cardiomyopathy, hypoketotic hypoglycemia, and sudden cardiac death 1, 2.
Diagnosis and Initial Assessment
Primary carnitine deficiency is a genetic disorder of the cellular carnitine-transporter system caused by mutations in the SLC22A5 gene 3. The diagnosis is established through:
- Plasma free carnitine concentration <5 μM (normal 25-50 μM) 2
- Acyl-to-free carnitine ratio >0.4 (normal ≤0.25) 3
- Genetic testing confirming SLC22A5 mutations 2
When evaluating suspected deficiency, simultaneously measure blood triglycerides, liver function tests (AST, ALT), glucose, lactate, ammonium, and urine ketones 3.
Once diagnosed, immediately perform baseline assessments including echocardiogram, electrocardiogram, creatine kinase, liver transaminases, and pre-prandial blood glucose 2.
Treatment Protocol
Primary Treatment: L-Carnitine Supplementation
The FDA-approved indication for CARNITOR® (levocarnitine) specifically addresses primary systemic carnitine deficiency presenting with recurrent Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy 1.
Dosing:
- Standard pharmacologic dose: 50-400 mg/kg/day divided into three doses 3, 2
- Adults often receive 3 g/day 3
- Treatment must be lifelong and continuous 4, 2
Critical Management Points
Avoid fasting - This is essential to prevent metabolic decompensation and hypoketotic hypoglycemia 5. The disorder impairs fatty acid β-oxidation, making patients dependent on glucose during fasting states.
Acute illness management:
- High-calorie infusion during metabolic crises 5
- Frequent plasma carnitine monitoring 2
- Measure ketones during emergencies to detect metabolic decompensation early 5
Clinical Manifestations by Age
The disease presents differently across age groups 3, 2:
- Infants (typically by age 5): Hypoketotic hypoglycemia, hepatomegaly, elevated transaminases, hyperammonemia
- Childhood: Skeletal myopathy, elevated creatine kinase, cardiomyopathy
- Adulthood: Cardiomyopathy, arrhythmias, fatigability
Severe complications without treatment include: cardiomyopathy, arrhythmia, sudden death, rhabdomyolysis, muscle weakness, and basal ganglia damage 3, 5.
Monitoring and Surveillance
While formal surveillance guidelines are lacking, the following schedule is recommended 2:
- Annual: Echocardiogram and electrocardiogram
- Regular: Plasma carnitine levels to ensure adequate supplementation
- During acute illness: Creatine kinase and liver transaminases
Treatment Response and Prognosis
Carnitine supplementation can reverse clinical symptoms, particularly cardiomyopathy 1, 4, 2. One case demonstrated complete normalization of left ventricular ejection fraction within weeks of restarting treatment after non-compliance led to heart failure 4. Another case showed resolution of basal ganglia abnormalities on MRI after treatment, though cerebral atrophy persisted 5.
The prognosis is favorable with continuous treatment 2. However, discontinuation of therapy—even after years of successful treatment—can lead to recurrent severe heart failure and life-threatening complications 4.
Critical Pitfall: Transition to Adult Care
The transition period from pediatric to adult care represents a high-risk time for non-compliance 4. Young adults may discontinue medication believing they are healthy, leading to catastrophic decompensation years later. Emphasize disease education and self-management before this transition, as even brief interruptions in therapy can be fatal.
Special Considerations
Pregnancy: Women with primary carnitine deficiency planning pregnancy should consult a metabolic specialist before conception, as carnitine levels typically decrease during pregnancy and supplementation requirements may increase 2.
Side effects at therapeutic doses (approximately 3 g/day) can include nausea, vomiting, abdominal cramps, diarrhea, and fishy body odor 3. Rarer effects include muscle weakness in uremic patients and seizures in those with seizure disorders 3.
Family screening: This is an autosomal recessive condition with 25% recurrence risk. Carrier screening should use targeted SLC22A5 mutation analysis, not plasma carnitine levels, as the latter is insufficient for determining carrier status 2.